In this article, we will discuss Cathie Wood stocks that are on sale now. If you want to explore similar stocks, you can also take a look at 5 Cathie Wood Stocks that are on Sale Now.
ARK Investment Management's founder and CEO, Cathie Wood, has been recognized as one of the most influential investors in the world owing to her stock-picking prowess that often generate above-average market returns over the long term. Founded in 2014, Ark Innovation ETF (ARKK) is her flagship fund that elicits strong interest and following on Wall Street.
The fund oversees about $25 billion in assets under management, less than half the $60 billion it controlled in 2021. Despite shrinking in recent yeast, Ark Innovation Fund continues to attract billions of dollars from investors who are fond of Wood's investment strategy stock picking prowess. The hedge fund manager has relied on the thematic investment strategy to generate enormous returns in capital over a short period.
Wood is best known for bets on companies with high earnings growth potential. While her investment strategy courts extreme levels of risks, including momentum, liquidity, valuation, and financial health, performance tends to be to the extreme on the highs of the lows.
The fund had one of its best years after inception in 2017 as it posted an impressive 87.4% gain driven by a 1,300% run-up in Grayscale Bitcoin Trust. The run came as Bitcoin exploded to record highs of $20,000 a coin. However, it was in 2020 that Wood would make a name for herself on Wall Street as she posted a 152.5% gain with her flagship fund.
Tesla, Inc. (NASDAQ:TSLA) is one of the stocks that have always propelled Woods to impressive gains in the market. She has always been bullish about the electric vehicle giant despite it facing valuation concerns. The high-growth stock accounts for nearly 8% of the portfolio manager exchange-traded funds. According to Woods, the automaker can reach $2,000 a share by 2027.
Woods was one of the early investors to take advantage of the artificial intelligence boom. The super investor placed big bets on artificial intelligence plays, including Nvidia, while also insisting Tesla offered solid exposure to the disruptive innovation.
While the flagship fund Ark Innovation ETF exited its position on NVIDIA Corporation (NASDAQ:NVDA) early, missing out on a blockbuster run, some of Woods's other ETFs still have positions in the ETF. Other companies that Wood expects to benefit from the AI boom include UiPath Inc. (NYSE:PATH), which is a robotic process automation software company, and Twilio Cloud Communication Company, which allows businesses to develop and integrate various communication channels.
Wood's aggressive investment strategy has also seen her seek growth by investing in risky assets, including cryptocurrencies. The hedge fund manager has been bullish about Bitcoin even as other high-profile investors term it a scam. In January, Wood raised her firm's 2030 price of the flagship cryptocurrency to $1 million.
According to Woods, Bitcoin has always been a perfect insurance policy for an uncertain economic world. In addition to investing in Bitcoin, she has also taken stakes in Coinbase Global, Inc. (NASDAQ:COIN), one of the largest cryptocurrency exchanges.
She has also expressed her optimistic outlook on the impending approval of the Bitcoin exchange-traded fund by the US Securities and Exchange Commission. The portfolio manager expects the approval to enable individual and institutional investors to gain Bitcoin exposure.
Through her flagship fund, Ark Innovation ETF, she invests heavily in disruptive technologies such as artificial intelligence, autonomous vehicles, and genomic medicine.
These Cathie Wood Stocks Are On Sale Now
Cathie Wood of ARK Investment Management
Since its launch nine years ago, the flagship fund has generated significant returns and, in the process, bagged $310 million in fees. The fund charges an annual management fee of 0.75%, nearly double the average of other actively managed funds.
Nevertheless, Woods's investment fund has generated poor results in recent years. The fund was on the receiving end last year as it plunged by nearly 70% as the overall stock market turned bearish on the Federal Reserve embarking on an aggressive interest rate hike. The losses were more than triple the 21% plunge recorded in 2021. Data shows that the flagship fund has lost $9.5 billion on risky bets in recent years.
While the fund is up by about 25% year to date, a number of stocks have continued to pull the funds lower. The stocks have been a big disappointment, edging lower despite the overall market turning bullish. The double-digit percentage losses recorded by some of the stocks affirm that even market gurus are not immune to mistakes regarding stock picking.
Our Methodology
Cathie Wood's strategy of investing in small, often loss-making companies promising long returns has crumbled amid the high-interest rate environment and growing recession risks. High inflation levels and the Federal Reserve's hawkish policies have taken a significant toll on some of Woods's stock picks, depicted by the losses generated year to date. We have compiled some of the stocks that continue to take a toll on Wood's portfolio. The stocks are ranked chronologically based on the losses generated year to date. We have also reported the hedge fund view on each stock, which was obtained from Insider Monkey’s database of 910 leading hedge funds tracked as of the end of Q2 2023.
Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is a company that designs, designs, and markets commercial aero structures worldwide. The company operates through three segments: commercial Defense, space, and Aftermarket.
Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is down by nearly 17% year to date, a situation compounded by the company announcing $105 million in losses on Boeing and Airbus aircraft production. Its long-term prospects also look bleak following the confirmation of a bleak cash flow for the rest of the year.
Amid the concerns, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is currently rated as a ‘Hold’ on Wall Street with a $24.76 price target implying 47% upside potential.
According to Insider Monkey’s second quarter database, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) was part of 30 hedge fund portfolios.
18. Adyen N.V. (OTC:ADYEY)
Number of Hedge Fund Holders: N/A
Year to Date Loss: 29%
Adyen N.V. (OTC:ADYEY) offers a payment platform that integrates a payment stack, including a gateway, risk management processing, and settlement services. The company also provides a back-end infrastructure for authorizing payments.
The Dutch payment giant has been on the receiving end, its sentiments having taken a hit on weak earnings, raising concerns about its valuation. The company delivered earnings that missed expectations, a rare miss since it went public in 2018. The stock is currently rated as a Hold, having tanked by 29% year to date.
FARO Technologies, Inc. (NASDAQ:FARO) designs develops, and manufactures software-driven three-dimensional measurement imaging and realization solutions. The company offers FaroArm, a portable articulated measurement arm, and CAM2 software programs. While the stock is down by 41% year to date, it is still rated as a Moderate Buy.
According to Insider Monkey’s second-quarter database, 21 hedge funds were bullish on FARO Technologies, Inc. (NASDAQ:FARO), compared to 17 funds in the prior quarter.
AudioCodes Ltd. (NASDAQ:AUDC) is a communication equipment company that provides advanced communications software products and productivity solutions. Its solutions are used to enable unified communications contacts centers and hosted business services.
The stock has underperformed the overall market by the 43% year-to-date slide. In contrast, the S&P 500 has gained about 15%. Following the steep sell-off, the stock is rated as a Moderate Sell with an $10 price target implying 1.21% downside potential.
According to Insider Monkey’s second quarter database, 11 hedge funds were bullish on AudioCodes Ltd. (NASDAQ:AUDC), compared to 9 funds in the earlier quarter.
Together with its subsidiaries, Silicom Ltd. (NASDAQ:SILC) designs, manufactures, and markets high-performance networking and data infrastructure solutions. Consequently, it offers server network interface cards and smart cards. The stock has disappointed Cathie Wood's portfolio, having tanked 44% year to date.
As Insider Monkey’s database for Q2 reveals, Silicom Ltd. (NASDAQ:SILC) was owned by 9 hedge funds, no different from the previous quarter.
Xometry, Inc. (NASDAQ:XMTR) operates an online marketplace that allows buyers to source manufactured parts and assemblies. It also provides computer numerical control manufacturing sheet metal forming, sheet cutting, and 3D printing.
Xometry, Inc. (NASDAQ:XMTR) has underperformed the overall Wood's portfolio after warning early in the year of slower growth ahead. The company has struggled to make a mark amid its push to become a leader in 3D printing or computer-controlled manufacturing processes. The stock is down by 50% year to date and is rated as a Moderate Buy on Wall Street with a $24.71 price target implying a 49.31% upside potential.
Insider Monkey’s Q2 database shows that Xometry, Inc. (NASDAQ:XMTR) was held by 16 hedge funds, unchanged from the previous quarter.
PyroGenesis Canada Inc. (NASDAQ:PYR) is a company that designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, which enhances metal recovery from dross without hazardous by-products.
PyroGenesis Canada Inc. (NASDAQ:PYR) hit 52-week lows as the provincial regulator triggered administrative proceedings against the company's CEO in connection to a settlement agreement in 2018 with Phoenix Haute Technology. The administrator is seeking penalties totalling $407,165. The stock is down by 52% year to date.
According to Insider Monkey’s second-quarter database, 1 hedge fund was bullish on PyroGenesis Canada Inc. (NASDAQ:PYR), compared to 3 funds in the prior quarter.
Butterfly Network, Inc. (NYSE:BFLY) develops and commercializes ultrasound imaging solutions in the US. The company offers Butterfly IQ, a handheld and single-probe ultrasound system that connects with a smartphone, tablet, and computer system.
Butterfly Network, Inc. (NYSE:BFLY) delivered disappointing second-quarter results with a net loss of $0.14 a share on revenues of $18.49 million, down from $19.22 million delivered a year ago. Wall Street rates the stock as a Moderate Buy even though it is down by 54% year to date.
According to Insider Monkey’s second-quarter database, 15 hedge funds were bullish on Butterfly Network, Inc. (NYSE:BFLY), compared to 14 funds in the prior quarter.
JD.com, Inc. (NASDAQ:JD) is a Chinese company that offers supply chain-based technologies and services. The company offers computers, communication, consumer electronics, home appliances, and general merchandise. It also offers online marketplace services for third-party merchants.
JD.com, Inc. (NASDAQ:JD) has struggled to bounce back following regulators' crackdown on Chinese internet giants. In addition, the company has struggled in the market with disappointing earnings results and deteriorating economic conditions in Mainland China. Consequently, the stock has plunged 55% year to date even as analysts maintain a Moderate Buy on the stock with a $44.34 price target, implying 72.19% upside potential.
According to Insider Monkey’s second-quarter database, 64 hedge funds were bullish on JD.com, Inc. (NASDAQ:JD), compared to 59 funds in the prior quarter.
Cerus Corporation (NASDAQ:CERS) is a biomedical products company that develops and commercializes the INTERCEPT Blood System that enhances blood safety. The system is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation (NASDAQ:CERS) delivered $38.9 million in product revenue in Q2, a decline from $41 million the prior year. Net loss soared to $13.3 million or $0.07 a share compared to $8.4 million or 0.05 a share delivered last year.
Cerus Corporation (NASDAQ:CERS) is down by 57% year to date and is currently rated as a Moderate Buy with a $4 a share price target implying 153.16% upside potential.
As of the end of the second quarter of 2023, 18 hedge funds had stakes in Cerus Corporation (NASDAQ:CERS).
PhenomeX Inc. (NASDAQ:CELL) is a cell biology company that enables scientists to reveal insights into cell function and obtain the behavior of each cell. Its arsenal of tools enables unparalleled resolution and speed while looking to advance discoveries to improve the prevention and treatment of diseases.
After underperforming for the better part of the year, the cell biology company has emerged as an acquisition target. Bruker has reached an agreement to acquire the company for a total equity value of $108 million. The stock is down by 60.8% year to date and is rated as a Hold with a $1 share price target implying 0.19% upside potential.
Insider Monkey’s database of hedge funds shows that 14 hedge funds had stakes in PhenomeX Inc. (NASDAQ:CELL) during the second quarter of 2023.
Moderna, Inc. (NASDAQ:MRNA) is a biotech company that uses messenger RNA to create treatments and vaccines for infections and rare and heart diseases. It also works on respiratory vaccines, including COVID-19 influenza and spikevax.
Moderna, Inc. (NASDAQ:MRNA) prospects in the market have taken a significant hit due to a decline in demand for the COVID-19 vaccine, which has raked billions in revenues in previous years. Consequently, the stock has plunged 61% year to date. Amid the underperformance, Moderna is still rated as a Moderate Buy with a $123.23 price target, implying a 75.52% upside potential.
Moderna, Inc. (NASDAQ:MRNA) was in 40 hedge fund portfolios, as per Insider Monkey’s database for Q2, the same as the prior quarter.
Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company that delivers genetic therapies to address diseases by deploying gene editing technology. The company offers prime editors with Prime Editor Protein comprising of fusion between CAS protein and reverse transcriptase enzyme.
Since going public last year, Prime Medicine, Inc. (NASDAQ:PRME) has underperformed the overall market. While the stock is rated as a Moderate Buy, it is down by 64% year to date. The consensus price target on the stock is $20.75, implying 211% upside potential.
According to Insider Monkey’s second quarter database, 12 hedge funds were bullish on Prime Medicine, Inc. (NASDAQ:PRME), compared to 13 funds in the prior quarter.
Codexis, Inc. (NASDAQ:CDXS) is a company that discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services that allow people to perform chemistry screening. After a poor run of form early in the year, the company sentiments received a boost after leading investment management firm BlackRock increased stakes in the company.
The hedge fund acquired 882,588 shares for a 10.4% stake in Codexis, Inc. (NASDAQ:CDXS). Nevertheless, the stock is still down by 64% year to date and remains under immense pressure. Analysts on Wall Street rate the stock as a ‘Strong Buy’ with a $7.38 share price target, implying 272% upside potential.
Insider Monkey’s database of 910 hedge funds shows that 18 hedge funds had stakes in Codexis, Inc. (NASDAQ:CDXS) at the end of Q2 2023.
